Lev Reports Data From Cinryze Studies

Lev Pharmaceuticals presented results from a Phase III trial of Cinryze in patients with acute attacks of hereditary angioedema (HAE), a genetic condition that causes recurrent and potentially life-threatening inflammation in the larynx, abdomen, face, extremities and urogenital tract.

The results from the double-blind, placebo-controlled trial showed patients experiencing an HAE attack who received treatment with Cinryze saw a reduction in symptoms at a median time of two hours compared with more than four hours for patients who received placebo, Lev said.

The company also reported that prophylactic treatment with Cinryze could prevent HAE attacks associated with surgery.